Search Results

Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the most notable here.

BioSpace’s NextGen companies are rising in one of the most confounding biotech markets ever experienced. Executives sounded off on how to keep your head above water during our webinar, Are We There Yet?

The industry sector focused on aging is only about 10 years old, but acting on what scientists already know, a new crop of biotechs, backed by investors, are taking a disease-centric approach to extending the human lifespan.

Biotech was starting to show signs of recovery after years of investor pullback—until new tariffs and economic uncertainty sent fresh shockwaves through an already fragile market.

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing environment where competition is steep and the usual roads to exit are uncertain.

EY’s 2025 Biotech Beyond Borders report provides a sobering snapshot of the industry’s financial health, with more and more companies facing cash runways of less than one year. The analyst firm’s leaders urge a return to basics for biotech.

The 2025 BIO International Convention (BIO2025), the world’s largest annual biotech event, will take place from June 16 to 19 (U.S. time) at the Boston Convention & Exhibition Center. This year, Taipei City Government is partnering with six Taipei-based biotech companies, including PanCAD.ai Co., Ltd., Instant NanoBiosensors Co., Ltd., Bened Biomedical Co., Ltd., Cancer Free Biotech Ltd., Xantho Biotechnology Co., Ltd., and Energenesis Biomedical Co., Ltd., to showcase their innovations at the Taiwan Pavilion (Booth #1645) in the Taipei Exhibition Area.

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical milestones on the horizon.

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the company is leveraging its unprecedented success in obesity to support young biotechs.

First-Ever Industry Analysis Shows 83% Message Overlap Forcing Biotechs Into Costly Talent Bidding Wars